Amedisys Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Richard Ashworth

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO

Richard Ashworth (48 yo)

less than a year

Tenure

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Scott Ginn	Executive VP	5.9yrs	US$4.16m	0.055% $ 29.4m
Michael North	Chief Information Officer	6.8yrs	US$1.19m	0% $ 0
Denise Bohnert	Chief Compliance Officer	4yrs	US$899.96k	no data
Nick Muscato	Chief Strategy Officer	no data	US$1.90m	0.0050% $ 2.7m
Richard Ashworth	President	less than a year	no data	no data
Allyson Guidroz	Chief Accounting Officer & Principal Accounting Officer	less than a year	no data	0.0096% $ 5.1m
Pete Hartley	CTO & Senior VP of Business Operations Systems	no data	no data	no data
Jennifer Griffin	Senior VP	less than a year	no data	no data
Kendra Kimmons	VP of Marketing & Communications & Media Relations	no data	no data	no data
Adam Holton	Chief People Officer	less than a year	no data	0.020% $ 10.7m
Francis Mayer	Senior Vice President of Development	no data	no data	no data
David Castille	Managing Director of Treasury/Finance	no data	no data	no data

1.0yrs

Average Tenure

50yo

Average Age

Experienced Management: AMED *'s management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Ashworth	President	less than a year	no data	no data
Paul Kusserow	Chairman	8.8yrs	US$4.08m	1.34% $ 714.0m
Bruce Perkins	Independent Director	8.4yrs	US$265.04k	0.054% $ 28.6m
Vickie Capps	Independent Director	3.8yrs	US$275.04k	0.0098% $ 5.2m
Molly Coye	Independent Director	3.8yrs	US$261.29k	0.0068% $ 3.6m
Julie Klapstein	Lead Independent DIrector	7.4yrs	US$277.54k	0.029% $ 15.4m
Jeffrey Rideout	Independent Director	7.4yrs	US$265.04k	0.0083% $ 4.5m
Teresa Kline	Independent Director	3.8yrs	US$265.04k	0.0098% $ 5.2m
Ivanetta Samuels	Independent Director	2.8yrs	US$250.04k	0.0030% $ 1.6m

3.8yrs

Average Tenure

62yo

Average Age

Experienced Board: AMED *'s board of directors are considered experienced (3.8 years average tenure).

Amedisys Management

Management criteria checks 1/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Recent updates

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

High number of new directors

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

High number of new directors

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

High number of new directors

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

High number of new directors

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$3.0m worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Investor sentiment improved over the past week

High number of new directors

High number of new directors

Independent Director recently sold Mex$42m worth of stock

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

Investor sentiment deteriorated over the past week

High number of new directors

President & COO recently sold Mex$1.5m worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold Mex$10m worth of stock

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

Independent Director recently bought Mex$5.3m worth of stock

Revenue misses expectations

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Defensive Index

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure